Media headlines about DexCom (NASDAQ:DXCM) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DexCom earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 47.1942682241018 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- DexCom, Inc. (DXCM) VP Patrick Michael Murphy Sells 12,500 Shares (americanbankingnews.com)
- Stocks Intraday Alert: Williams Partners LP (NYSE:WPZ), DexCom, Inc. (NASDAQ:DXCM), Platinum Group Metals Ltd … (stocksnewspoint.com)
- Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring (finance.yahoo.com)
- Edited Transcript of DXCM earnings conference call or presentation 1-Aug-18 8:30pm GMT (finance.yahoo.com)
- $239.45 Million in Sales Expected for DexCom, Inc. (DXCM) This Quarter (americanbankingnews.com)
Several brokerages recently issued reports on DXCM. BidaskClub cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Berenberg Bank raised DexCom from a “hold” rating to a “buy” rating and set a $140.00 price objective for the company in a report on Monday, August 6th. Oppenheimer set a $125.00 price objective on DexCom and gave the stock a “buy” rating in a report on Thursday, August 2nd. Canaccord Genuity raised their price target on DexCom from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, June 28th. Finally, BMO Capital Markets raised their price target on DexCom from $112.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. DexCom has a consensus rating of “Buy” and a consensus target price of $102.19.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. The business had revenue of $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The business’s revenue for the quarter was up 42.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.16) earnings per share. research analysts anticipate that DexCom will post -0.48 EPS for the current year.
In other news, VP Patrick Michael Murphy sold 12,500 shares of DexCom stock in a transaction on Friday, August 10th. The stock was sold at an average price of $124.18, for a total value of $1,552,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Doubleday sold 2,581 shares of DexCom stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $86.00, for a total value of $221,966.00. Following the completion of the sale, the executive vice president now directly owns 94,429 shares of the company’s stock, valued at approximately $8,120,894. The disclosure for this sale can be found here. In the last ninety days, insiders sold 159,900 shares of company stock valued at $16,018,313. Company insiders own 1.80% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.